EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling

Qingmei Li, Min Wu iD, John Mao, Tianxiang Zhang, Wenhao Yan, Xiuping Yan, Chuanjing Li, George Zhang, Yanhua Ding iD, Jiajia Mai iD, Hong Zhang iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.01541-25 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Qingmei Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nephrology, Children's Medical Center, The First Hospital of Jilin University, Jilin, China. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Renal Insufficiency. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Akeylink Biotechnology Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GST-HG171 is an orally administered inhibitor of the 3C-like protease that has been approved in China for the treatment of mild to moderate COVID-19. When co-administered with ritonavir, GST-HG171 is eliminated by the kidney. Therefore, this study evaluated the impact of renal impairment on its pharmacokinetics (PK), safety, and tolerability. A total of 24 participants were enrolled: 8 with normal renal function, 8 with mild renal impairment, and 8 with moderate renal impairment. Participants received 100 mg ritonavir at −12, 0, 12, and 24 h, with a single 150 mg dose of GST-HG171 co-administered at 0 h to maintain CYP3A inhibition. Compared with healthy subjects, mild renal impairment increased GST-HG171 exposure; the geometric least-squares mean ratios (90% confidence intervals) for C max , AUC 0 –t , and AUC 0–∞ were 118.15 (99.38–140.46), 139.48 (111.21–174.95), and 138.46 (111.19–172.42), respectively. Moderate impairment further increased exposure, with ratios of 131.81 (108.34–160.36), 186.18 (150.47–230.36), and 182.64 (148.03–225.33), respectively. Renal clearance was reduced by 22.7% and 52% in the mild and moderate impairment groups, respectively. GST-HG171 was generally tolerated across all groups, but adverse reactions related to hypertriglyceridemia should be monitored. Physiologically based PK modeling supported dose reductions for patients with renal impairment, recommending GST-HG171/ritonavir 100/100 mg twice daily for mild impairment and 50/100 mg twice daily for moderate impairment, administered for 5 days. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT06106126 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentRenal InsufficiencyAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCytochrome P-450 CYP3A InhibitorsDose-Response Relationship, DrugModels, BiologicalRitonavir

Stichwörter der Autor:innen

COVID-19GST-HG171PBPKclinical trialpharmacokineticsrenal impairmentsafety

Substanzen

Antiviral AgentsCytochrome P-450 CYP3A InhibitorsRitonavir

Autor:innen und Institutionen

  • Department of Pediatric Nephrology, Children's Medical Center, The First Hospital of Jilin University, Jilin, China.
  • Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
  • Fujian Akeylink Biotechnology Co., Ltd., Fuzhou, Fujian, China.

ORCID-Profile: Min Wu, Yanhua Ding, Jiajia Mai, Hong Zhang

Förderung

  • Fujian Akeylink Biotechnology Co., Ltd.

Zitieren

APA

Li, Q., Wu, M., Mao, J., Zhang, T., Yan, W., Yan, X., Li, C., Zhang, G., Ding, Y., Mai, J., & Zhang, H. (2026). Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.01541-25

Vancouver

Li Q, Wu M, Mao J, Zhang T, Yan W, Yan X, et al. Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.01541-25

BibTeX
@article{Li2026,
  author = {Li, Qingmei and Wu, Min and Mao, John and Zhang, Tianxiang and Yan, Wenhao and Yan, Xiuping and Li, Chuanjing and Zhang, George and Ding, Yanhua and Mai, Jiajia and Zhang, Hong},
  title = {Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.01541-25}
}
Kostenlos starten →